Hassan M, Mercer RM, Maskell NA, et al. - Given a potential survival benefit has been suggested, by recent observations, in patients with malignant pleural effusion (MPE) who achieved successful pleurodesis vs those who experienced effusion recurrence after pleurodesis, researchers further examined this observation by analyzing two datasets of patients having MPE undergoing talc pleurodesis. Patients who had talc pleurodesis at Oxford Pleural Unit for MPE were included in dataset 1 and those enrolled in the TIME1 clinical trial were included in dataset 2. In dataset 1, mesothelioma, breast and lung cancer were the most common primary malignancies. In dataset 2, mesothelioma, lung and breast cancer were identified as the most common primary malignancies. In patients with MPE, achieving pleurodesis appeared to confer a survival benefit.